INTELLIA THERAPEUTICS INC COM USD0.0001INTELLIA THERAPEUTICS INC COM USD0.0001INTELLIA THERAPEUTICS INC COM USD0.0001

INTELLIA THERAPEUTICS INC COM USD0.0001

No trades
See on Supercharts
Next report date
Report period
EPS estimate
Revenue estimate
Market capitalization
‪1.70 B‬USD
−5.445USD
‪−481.19 M‬USD
‪36.27 M‬USD
‪99.79 M‬
Beta (1Y)
3.07
Employees (FY)
526
Change (1Y)
−72 −12.04%
Revenue / Employee (1Y)
‪68.96 K‬USD
Net income / Employee (1Y)
‪−914.81 K‬USD

About Intellia Therapeutics, Inc.


CEO
John M. Leonard
Headquarters
Cambridge
Founded
2014
FIGI
BBG00JRQS251
Intellia Therapeutics, Inc. is a clinical stage genome editing company, which engages in the development of curative therapeutics using the CRISPR/Cas9 system. Its CRISPR/Cas9 system transforms medicine by both producing therapeutics that permanently edit and/or correct disease-associated genes in the human body with a single treatment course, and creates engineered cells that can treat oncological and immunological diseases. The company was founded by Andrew May, Luciano Marraffini, Rodolphe Barrangou, Nessan Bermingham, Rachel Haurwitz, Erik Sontheimer, Jennifer Doudna, and Derrick Rossi in May 2014 and is headquartered in Cambridge, MA.
Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:
‪0.00‬

See all ideas 

Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Displays a symbol's price movements over previous years to identify recurring trends.

Frequently Asked Questions


The current price of 0JBU is 16.410 USD — it has increased by 1.72% in the past 24 hours. Watch INTELLIA THERAPEUTICS INC COM USD0.0001 stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on LSE exchange INTELLIA THERAPEUTICS INC COM USD0.0001 stocks are traded under the ticker 0JBU.
0JBU stock has risen by 14.92% compared to the previous week, the month change is a −8.58% fall, over the last year INTELLIA THERAPEUTICS INC COM USD0.0001 has showed a −40.99% decrease.
We've gathered analysts' opinions on INTELLIA THERAPEUTICS INC COM USD0.0001 future price: according to them, 0JBU price has a max estimate of 128.00 USD and a min estimate of 14.00 USD. Watch 0JBU chart and read a more detailed INTELLIA THERAPEUTICS INC COM USD0.0001 stock forecast: see what analysts think of INTELLIA THERAPEUTICS INC COM USD0.0001 and suggest that you do with its stocks.
0JBU reached its all-time high on Jun 30, 2021 with the price of 200.810 USD, and its all-time low was 13.980 USD and was reached on Oct 31, 2024. View more price dynamics on 0JBU chart.
See other stocks reaching their highest and lowest prices.
0JBU stock is 5.52% volatile and has beta coefficient of 3.07. Track INTELLIA THERAPEUTICS INC COM USD0.0001 stock price on the chart and check out the list of the most volatile stocks — is INTELLIA THERAPEUTICS INC COM USD0.0001 there?
Today INTELLIA THERAPEUTICS INC COM USD0.0001 has the market capitalization of ‪1.70 B‬, it has decreased by −9.59% over the last week.
Yes, you can track INTELLIA THERAPEUTICS INC COM USD0.0001 financials in yearly and quarterly reports right on TradingView.
INTELLIA THERAPEUTICS INC COM USD0.0001 is going to release the next earnings report on Feb 20, 2025. Keep track of upcoming events with our Earnings Calendar.
0JBU earnings for the last quarter are −1.34 USD per share, whereas the estimation was −1.39 USD resulting in a 3.61% surprise. The estimated earnings for the next quarter are −1.37 USD per share. See more details about INTELLIA THERAPEUTICS INC COM USD0.0001 earnings.
INTELLIA THERAPEUTICS INC COM USD0.0001 revenue for the last quarter amounts to ‪9.11 M‬ USD, despite the estimated figure of ‪8.28 M‬ USD. In the next quarter, revenue is expected to reach ‪8.81 M‬ USD.
0JBU net income for the last quarter is ‪−135.71 M‬ USD, while the quarter before that showed ‪−146.97 M‬ USD of net income which accounts for 7.66% change. Track more INTELLIA THERAPEUTICS INC COM USD0.0001 financial stats to get the full picture.
No, 0JBU doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Nov 10, 2024, the company has 526.00 employees. See our rating of the largest employees — is INTELLIA THERAPEUTICS INC COM USD0.0001 on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. INTELLIA THERAPEUTICS INC COM USD0.0001 EBITDA is ‪−527.52 M‬ USD, and current EBITDA margin is ‪−1.40 K‬%. See more stats in INTELLIA THERAPEUTICS INC COM USD0.0001 financial statements.
Like other stocks, 0JBU shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade INTELLIA THERAPEUTICS INC COM USD0.0001 stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So INTELLIA THERAPEUTICS INC COM USD0.0001 technincal analysis shows the sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating INTELLIA THERAPEUTICS INC COM USD0.0001 stock shows the sell signal. See more of INTELLIA THERAPEUTICS INC COM USD0.0001 technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.